Literature DB >> 9705607

cAMP analogues downregulate the expression of granulocyte macrophage colony-stimulating factor (GM-CSF) in human bone marrow stromal cells in vitro.

G Bug1, J Aman, C Huber, C Peschel, H G Derigs.   

Abstract

The stimulation of granulocyte macrophage-colony stimulating factor (GM-CSF) by interleukin-1 (IL-1) has been shown to be counteracted in different mesenchymal cell systems by cyclic adenosine monophosphate (cAMP) agonists. The aim of this study was the evaluation of different cAMP agonists on GM-CSF expression in human bone marrow stromal cells. Incubation of secondary haematopoietic progenitor cell deprived human stromal cell cultures with IL-1 or TNF-alpha induced GM-CSF protein expression in culture supernatants and GM-CSF-mRNA in adherent stromal cells. The coincubation with 8-bromo-cAMP (8BrcAMP), a water soluble cAMP analogue, inhibited this GM-CSF stimulation at the protein and the mRNA level. This effect was dose dependent with a maximal inhibition of about 65% occurring at a 8BrcAMP concentration of 0.75 mM. In addition to 8BrcAMP, other cAMP agonists such as dibutyryl-cAMP, forskolin, pertussis toxin, or prostaglandin E2 (PGE2) had the same inhibitory effect on GM-CSF stimulation by IL-1. Coincubation with the cyclooxygenase inhibitor indomethacin had no significant influence on GM-CSF expression in stromal cells. Our results provide evidence that the previously described inhibitory effect of cAMP agonist PGE2 on haematopoietic progenitor cells in vivo is, at least in part, mediated by modulating the expression of GM-CSF in bone marrow stromal cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9705607      PMCID: PMC1781848          DOI: 10.1080/09629359891135

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  26 in total

1.  Transcriptional and posttranscriptional regulation of macrophage-specific colony stimulating factor gene expression by tumor necrosis factor. Involvement of arachidonic acid metabolites.

Authors:  M L Sherman; B L Weber; R Datta; D W Kufe
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

2.  Dissecting the hematopoietic microenvironment. VIII. Clonal isolation and identification of cell types in murine CFU-F colonies by limiting dilution.

Authors:  Q R Wang; N S Wolf
Journal:  Exp Hematol       Date:  1990-05       Impact factor: 3.084

3.  Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate.

Authors:  P J Knudsen; C A Dinarello; T B Strom
Journal:  J Immunol       Date:  1986-11-15       Impact factor: 5.422

4.  Regulation of cytokine and growth factor gene expression in human bone marrow stromal cells transformed with simian virus 40.

Authors:  J L Slack; J Nemunaitis; D F Andrews; J W Singer
Journal:  Blood       Date:  1990-06-15       Impact factor: 22.113

5.  IL1 induces proliferation and IL6 mRNA expression in a human astrocytoma cell line: positive and negative modulation by chorela toxin and cAMP.

Authors:  T Kasahara; H Yagisawa; K Yamashita; Y Yamaguchi; Y Akiyama
Journal:  Biochem Biophys Res Commun       Date:  1990-03-30       Impact factor: 3.575

6.  Role for cyclic AMP in the postreceptor control of cytokine-stimulated stromal cell growth factor production.

Authors:  H G Derigs; G S Burgess; D Klingberg; T S Nahreini; D Y Mochizuki; D E Williams; H S Boswell
Journal:  Leukemia       Date:  1990-07       Impact factor: 11.528

7.  Characterization of murine bone marrow and spleen-derived stromal cells: analysis of leukocyte marker and growth factor mRNA transcript levels.

Authors:  J M Gimble; C Pietrangeli; A Henley; M A Dorheim; J Silver; A Namen; M Takeichi; C Goridis; P W Kincade
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

8.  In vivo modulation of murine myelopoiesis following intravenous administration of prostaglandin E2.

Authors:  P Gentile; D Byer; L M Pelus
Journal:  Blood       Date:  1983-11       Impact factor: 22.113

9.  In vivo modulation of myelopoiesis by prostaglandin E2. IV. Prostaglandin E2 induction of myelopoietic inhibitory activity.

Authors:  P S Gentile; L M Pelus
Journal:  J Immunol       Date:  1988-10-15       Impact factor: 5.422

10.  In vivo modulation of myelopoiesis by prostaglandin E2. III. Induction of suppressor cells in marrow and spleen capable of mediating inhibition of CFU-GM proliferation.

Authors:  L M Pelus; P S Gentile
Journal:  Blood       Date:  1988-06       Impact factor: 22.113

View more
  3 in total

1.  Murine myeloid progenitor responses to GM-CSF and eosinophil precursor responses to IL-5 represent distinct targets for downmodulation by prostaglandin E(2).

Authors:  M I Gaspar Elsas; D Joseph; L Lintomen; E S Maximiano; M Bodstein; P Xavier Elsas; B B Vargaftig
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

2.  Suppression of granulocyte/macrophage colony-stimulating factor release from human monocytes by cyclic AMP-elevating drugs: role of interleukin-10.

Authors:  P M Seldon; M A Giembycz
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

3.  Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture.

Authors:  Y Okada; J A Lorenzo; A M Freeman; M Tomita; S G Morham; L G Raisz; C C Pilbeam
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.